Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Geron (GERN) EBITDA: 2010-2025

Historic EBITDA for Geron (GERN) over the last 16 years, with Sep 2025 value amounting to -$13.9 million.

  • Geron's EBITDA rose 50.78% to -$13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$63.1 million, marking a year-over-year increase of 69.66%. This contributed to the annual value of -$173.7 million for FY2024, which is 10.42% up from last year.
  • Geron's EBITDA amounted to -$13.9 million in Q3 2025, which was down 11.51% from -$12.5 million recorded in Q2 2025.
  • Geron's EBITDA's 5-year high stood at -$12.5 million during Q2 2025, with a 5-year trough of -$69.3 million in Q2 2024.
  • For the 3-year period, Geron's EBITDA averaged around -$37.3 million, with its median value being -$40.1 million (2023).
  • In the last 5 years, Geron's EBITDA crashed by 85.70% in 2023 and then spiked by 82.04% in 2025.
  • Geron's EBITDA (Quarterly) stood at -$31.0 million in 2021, then slumped by 35.40% to -$42.0 million in 2022, then decreased by 29.41% to -$54.3 million in 2023, then soared by 63.07% to -$20.1 million in 2024, then spiked by 50.78% to -$13.9 million in 2025.
  • Its EBITDA was -$13.9 million in Q3 2025, compared to -$12.5 million in Q2 2025 and -$16.7 million in Q1 2025.